Cogent Biosciences, Inc. (COGT)
NASDAQ:COGT
Top Page
Cogent Biosciences
(NASDAQ:COGT)
Select Model
Select Model
Rating:46Neutral
Price Target:
$35.00
▼(-4.16% Downside)
Action:ReiteratedDate:04/02/26
The score is primarily weighed down by very weak financial performance (no meaningful revenue, widening losses, and persistent cash burn) alongside increased leverage risk. Technicals are mixed with modest momentum but a weaker short-term trend, and valuation is constrained by ongoing losses and no dividend support.
Positive Factors
Regulatory progress: NDA submission
Submission of an NDA for bezuclastinib under the FDA Real‑Time Oncology Review program, combined with Breakthrough Therapy designation, materially de‑risks the lead program. A regulatory approval or accelerated review would create the company’s first commercial pathway, shifting the firm from pre‑commercial to potential revenue generation and improving partner and payer interest over the coming months.
Negative Factors
No meaningful revenue
The company remains pre‑commercial with essentially no product revenue across multiple years. That structural absence of operating income forces reliance on external financing for R&D and operations, elevating dilution and funding risk and making long‑term progress contingent on successful trial and approval outcomes.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory progress: NDA submission
Submission of an NDA for bezuclastinib under the FDA Real‑Time Oncology Review program, combined with Breakthrough Therapy designation, materially de‑risks the lead program. A regulatory approval or accelerated review would create the company’s first commercial pathway, shifting the firm from pre‑commercial to potential revenue generation and improving partner and payer interest over the coming months.
Read all positive factors
Cogent Biosciences (COGT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.90B
Dividend YieldN/A
Average Volume (3M)2.30M
Price to Earnings (P/E)―
Beta (1Y)0.92
Revenue GrowthN/A
EPS Growth4.32%
CountryUS
Employees205
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.61
Shares Outstanding162,308,820
10 Day Avg. Volume2,684,207
30 Day Avg. Volume2,296,321
Financial Highlights & Ratios
PEG Ratio-2.00
Price to Book (P/B)3.77
Price to Sales (P/S)0.00
P/FCF Ratio-9.03
Enterprise Value/Market Cap0.99
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.51K
Enterprise Value/Ebitda-17.59
Forecast
1Y Price Target
$52.55Price Target Upside43.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-2.12
Revenue Forecast (FY)$17.81M
Cogent Biosciences Business Overview & Revenue Model
Company Description
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mut...
How the Company Makes Money
null...
Cogent Biosciences Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
56
Neutral
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -4.62M | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -328.74M | -271.59M | -204.54M | -141.96M | -73.56M |
| Net Income | -328.94M | -255.86M | -192.41M | -140.24M | -72.27M |
Balance Sheet | |||||
| Total Assets | 937.61M | 327.90M | 313.44M | 300.81M | 232.09M |
| Cash, Cash Equivalents and Short-Term Investments | 900.76M | 287.08M | 265.71M | 259.28M | 219.68M |
| Total Debt | 253.15M | 17.47M | 18.85M | 19.65M | 3.15M |
| Total Liabilities | 301.24M | 71.61M | 55.63M | 45.08M | 17.91M |
| Stockholders Equity | 636.37M | 256.29M | 257.80M | 255.74M | 214.18M |
Cash Flow | |||||
| Free Cash Flow | -266.00M | -208.36M | -156.42M | -125.50M | -60.48M |
| Operating Cash Flow | -264.44M | -207.79M | -153.62M | -118.64M | -58.76M |
| Investing Cash Flow | -399.53M | 38.28M | -97.82M | -124.72M | -1.72M |
| Financing Cash Flow | 878.23M | 214.45M | 163.54M | 163.56M | 37.98M |
Cogent Biosciences Technical Analysis
Positive
36.52
Price Trends
36.72
Negative
37.36
Negative
25.60
Positive
Market Momentum
>-0.01
Negative
51.08
Neutral
52.36
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For COGT, the sentiment is Positive. The current price of 36.52 is above the 20-day moving average (MA) of 35.79, below the 50-day MA of 36.72, and above the 200-day MA of 25.60, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 51.08 is Neutral, neither overbought nor oversold. The STOCH value of 52.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for COGT.
Cogent Biosciences Risk Analysis
Cogent Biosciences disclosed 61 risk factors in its most recent earnings report. Cogent Biosciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cogent Biosciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | $1.67B | 13.56 | 19.84% | ― | 21.13% | 50.86% | |
54 Neutral | $2.79B | ― | -7.31% | ― | -84.07% | -157.71% | |
53 Neutral | $1.57B | ― | -6.93% | ― | 27.51% | 38.72% | |
52 Neutral | $2.88B | ― | -11.10% | ― | 5376.27% | 20.97% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $5.90B | ― | -100.22% | ― | ― | 4.32% | |
43 Neutral | $2.53B | ― | -32.80% | ― | ― | -34.96% |
* Healthcare Sector Average
COGT
Cogent Biosciences
36.49
31.62
649.28%
IDYA
IDEAYA Biosciences
32.35
15.37
90.52%
BEAM
Beam Therapeutics
30.30
13.02
75.35%
IRON
Disc Medicine
70.48
29.17
70.61%
HRMY
Harmony Biosciences Holdings
29.29
0.54
1.88%
IMCR
Immunocore Holdings
31.69
4.38
16.04%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.